Toxicidad aguda de la SBRT en cáncer de próstata localizado: estudio multicéntrico español

IF 1.2 4区医学 Q3 UROLOGY & NEPHROLOGY

Actas urologicas espanolas Pub Date : 2025-10-01 DOI:10.1016/j.acuro.2025.501798

S.E. Romero Zoghbi , F. López Campos , D. Sanz-Rosa , J. Fernández Ibiza , I.J. Thuissard-Vasallo , C. Andreu-Vázquez , C. Laria , J. Andreescu Yagüe , E. Krumina , A. Ocanto , M. Mateos , L.A. Glaría , J.A. García Cuesta , D. Gonsalves , C. Fernández , D. Esteban , J. Begara de la Fuente , D. Rivas , E. López Ramírez , L. Aakki , F. Couñago

{"title":"Toxicidad aguda de la SBRT en cáncer de próstata localizado: estudio multicéntrico español","authors":"S.E. Romero Zoghbi , F. López Campos , D. Sanz-Rosa , J. Fernández Ibiza , I.J. Thuissard-Vasallo , C. Andreu-Vázquez , C. Laria , J. Andreescu Yagüe , E. Krumina , A. Ocanto , M. Mateos , L.A. Glaría , J.A. García Cuesta , D. Gonsalves , C. Fernández , D. Esteban , J. Begara de la Fuente , D. Rivas , E. López Ramírez , L. Aakki , F. Couñago","doi":"10.1016/j.acuro.2025.501798","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Stereotactic body radiation therapy (SBRT) has emerged as an effective option for the treatment of localized prostate cancer; however, data from real-world clinical practice remain limited.</div></div><div><h3>Material and Methods</h3><div>Between January 2020 and December 2023, 251 patients with localized prostate cancer treated with SBRT were included in 12 centers in Spain. The treatment volume included prostate+/- seminal vesicles, without prophylactic pelvic radiotherapy. A dose of 35-40Gy was prescribed in 5 fractions, every other day. Acute genitourinary (GU), gastrointestinal (GI) and sexual toxicity was assessed up to 6 months post-treatment using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</div></div><div><h3>Results</h3><div>A total of 251 patients were classified based on the National Comprehensive Cancer Network (NCCN®) classification. Four percent of patients had very low-risk disease, 26.3% low-risk, and 66.5% intermediate-risk (27.1% favorable intermediate and 39.4% unfavorable intermediate). Additionally, 2.8% were classified as high-risk and 0.4% as very high-risk. The median patient age was 72 years (range: 65–76), and the baseline PSA was 6.7ng/mL (range: 5.3–8.7). The median SBRT dose was 40Gy (range: 35–40Gy). Grade 2 acute GU toxicity occurred in 6.4% of patients, and grade 3 in 0.4%. Grade 2 GI toxicity was observed in 0.8%, with no cases of grade 3 GI toxicity. Regarding sexual toxicity, 11.2% of patients experienced grade 2, and 1.2% grade 3 toxicity.</div></div><div><h3>Conclusions</h3><div>Five-fraction SBRT is a feasible and safe treatment with a low incidence of acute toxicity.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"49 8","pages":"Article 501798"},"PeriodicalIF":1.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0210480625001160","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Stereotactic body radiation therapy (SBRT) has emerged as an effective option for the treatment of localized prostate cancer; however, data from real-world clinical practice remain limited.

Material and Methods

Between January 2020 and December 2023, 251 patients with localized prostate cancer treated with SBRT were included in 12 centers in Spain. The treatment volume included prostate + /- seminal vesicles, without prophylactic pelvic radiotherapy. A dose of 35-40 Gy was prescribed in 5 fractions, every other day. Acute genitourinary (GU), gastrointestinal (GI) and sexual toxicity was assessed up to 6 months post-treatment using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Results

A total of 251 patients were classified based on the National Comprehensive Cancer Network (NCCN®) classification. Four percent of patients had very low-risk disease, 26.3% low-risk, and 66.5% intermediate-risk (27.1% favorable intermediate and 39.4% unfavorable intermediate). Additionally, 2.8% were classified as high-risk and 0.4% as very high-risk. The median patient age was 72 years (range: 65–76), and the baseline PSA was 6.7 ng/mL (range: 5.3–8.7). The median SBRT dose was 40 Gy (range: 35–40 Gy). Grade 2 acute GU toxicity occurred in 6.4% of patients, and grade 3 in 0.4%. Grade 2 GI toxicity was observed in 0.8%, with no cases of grade 3 GI toxicity. Regarding sexual toxicity, 11.2% of patients experienced grade 2, and 1.2% grade 3 toxicity.

Conclusions

Five-fraction SBRT is a feasible and safe treatment with a low incidence of acute toxicity.

查看原文本刊更多论文

SBRT在局部前列腺癌中的急性毒性：西班牙多中心研究

立体定向放射治疗（SBRT）已成为治疗局限性前列腺癌的有效选择；然而，来自真实世界临床实践的数据仍然有限。材料和方法在2020年1月至2023年12月期间，251名接受SBRT治疗的局限性前列腺癌患者被纳入西班牙12个中心。治疗容积包括前列腺+ /-精囊，无盆腔预防性放疗。35- 40gy的剂量分为5份，每隔一天服用一次。使用不良事件通用术语标准（CTCAE） v5.0对治疗后6个月的急性泌尿生殖系统（GU）、胃肠道（GI）和性毒性进行评估。结果251例患者按照国家综合癌症网络（NCCN®）分类。4%的患者为极低风险，26.3%为低风险，66.5%为中风险（27.1%为有利的中间风险，39.4%为不利的中间风险）。此外，2.8%的人被列为高危人群，0.4%的人被列为高危人群。患者中位年龄为72岁（范围：65-76），基线PSA为6.7 ng/mL（范围：5.3-8.7）。SBRT的中位剂量为40 Gy（范围：35-40 Gy）。6.4%的患者发生2级急性GU毒性，0.4%的患者发生3级急性GU毒性。2级胃肠道毒性为0.8%，没有3级胃肠道毒性病例。关于性毒性，11.2%的患者出现2级毒性，1.2%出现3级毒性。结论五段式SBRT是一种安全可行、急性毒性低的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Actas urologicas espanolas UROLOGY & NEPHROLOGY-

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

46 days

期刊介绍： Actas Urológicas Españolas is an international journal dedicated to urological diseases and renal transplant. It has been the official publication of the Spanish Urology Association since 1974 and of the American Urology Confederation since 2008. Its articles cover all aspects related to urology. Actas Urológicas Españolas, governed by the peer review system (double blinded), is published online in Spanish and English. Consequently, manuscripts may be sent in Spanish or English and bidirectional free cost translation will be provided.